Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer

Pharmacogenomics

Volumn 13, Issue 5, 2012, Pages 615-624

  Hamada, Akinobu ^a,b   Sasaki, Ji Ichiro ^a   Saeki, Sho ^b   Iwamoto, Norihiro ^c   Inaba, Megumi ^d   Ushijima, Sunao ^d   Urata, Maki ^e   Kishi, Hiroto ^e   Fujii, Shinji ^f   Semba, Hiroshi ^f   Kashiwabara, Kosuke ^g   Tsubata, Yukari ^h   Kai, Yuki ^b   Isobe, Takeshi ^h   Kohrogi, Hirotsugu ^b   Saito, Hideyuki ^a,b  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^d Kumamoto Central Hospital   (Japan)

^e KUMAMOTO CITY HOSPITAL   (Japan)

^f National Hospital Organization   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^h SHIMANE UNIVERSITY HOSPITAL   (Japan)

Author keywords

ABCB1; erlotinib; Japanese; P glycoprotein; pharmacokinetic; polymorphism; toxicity

Indexed keywords

ERLOTINIB;

ABCB1 GENE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DNA DETERMINATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG MECHANISM; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; JAPANESE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NUCLEOTIDE SEQUENCE; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; TREATMENT REFUSAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84859248858     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.176     Document Type: Article

References (48)

1. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 98(12), 1817-1824 (2007). (Pubitemid 350002184)
2. Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med. 352(20), 2136 (2005). (Pubitemid 40664319)
3. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
4. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer. correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004). (Pubitemid 38720929)
5. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10(8), 579-589 (2005). (Pubitemid 41429121)
6. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large Phase III studies. Clin. Cancer Res. 13(13), 3913-3921 (2007). (Pubitemid 47037599)
7. Lu JF, Eppler SM, Wolf J et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin. Pharmacol. Ther. 80(2), 136-145 (2006). (Pubitemid 44160689)
8. Mita AC, Papadopoulos K, De Jonge MJ et al. Erlotinib 'dosing-to-rash': a Phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br. J. Cancer 105(7), 938-944 (2011).
9. Evans WE, Mcleod HL. Pharmacogenomics- drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003). (Pubitemid 36159890)
10. Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol. 26(7), 1119-1127 (2008).
11. Hamilton M, Wolf JL, Rusk J et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 12(7 Pt 1), 2166-2171 (2006).
12. Hughes AN, O'Brien ME, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J. Clin. Oncol. 27(8), 1220-1226 (2009).
13. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8), 927-941 (2007). (Pubitemid 47359135)
14. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2(1), 48-58 (2002). (Pubitemid 37328807)
15. Shi Z, Peng XX, Kim IW et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATPbinding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67(22), 11012-11020 (2007). (Pubitemid 350145931)
16. Marchetti S, De Vries NA, Buckle T et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/ Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol. Cancer Ther. 7(8), 2280-2287 (2008).
17. Li J, Cusatis G, Brahmer J et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 6(3), 432-438 (2007). (Pubitemid 47328313)
18. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 1794(5), 860-871 (2009).
19. Aarnoudse AL, Van Schaik RH, Dieleman J et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin. Pharmacol. Ther. 80(4), 367-374 (2006). (Pubitemid 44479754)
20. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004). (Pubitemid 38130115)
21. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4(4), 397-410 (2003). (Pubitemid 36857176)
22. Hoffmeyer S, Burk O, Von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000). (Pubitemid 30183327)
23. Cusatis G, Gregorc V, Li J et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl Cancer Inst. 98(23), 1739-1742 (2006). (Pubitemid 44942712)
24. Hodges LM, Markova SM, Chinn LW et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genomics 21(3), 152-161 (2011).
25. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13(8), 481-494 (2003). (Pubitemid 37034590)
26. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007). (Pubitemid 46175758)
27. Kimchi-Sarfaty C, Marple AH, Shinar S et al. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8(1), 29-39 (2007). (Pubitemid 46157755)
28. Yamamoto N, Horiike A, Fujisaka Y et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother. Pharmacol. 61(3), 489-496 (2008). (Pubitemid 350275984)
29. Yamakawa Y, Hamada A, Nakashima R et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther. Drug Monit. 33(2), 244-250 (2011).
30. Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A. Liquid- chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796(1), 181-188 (2003). (Pubitemid 38352722)
31. Aarnoudse AJ, Dieleman JP, Visser LE et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet. Genomics 18(4), 299-305 (2008). (Pubitemid 351367523)
32. Skazik C, Wenzel J, Marquardt Y et al. P-glycoprotein (ABCB1) expression in human skin is mainly restricted to dermal components. Exp. Dermatol. 20(5), 450-452 (2011).
33. Seo T, Ishitsu T, Ueda N et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7(4), 551-561 (2006). (Pubitemid 43891412)
34. Yi SY, Hong KS, Lim HS et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. 76(5), 418-427 (2004).
35. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br. J. Clin. Pharmacol. 64(2), 185-191 (2007). (Pubitemid 47063248)
36. Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J. Clin. Pharm. Ther. 32(1), 89-95 (2007). (Pubitemid 46213944)
37. Xu P, Jiang ZP, Zhang BK, Tu JY, Li HD. Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology 82(3), 221-227 (2008).
38. Potocnik U, Glavac D, Dean M. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet. Cytogenet. 183(1), 28-34 (2008). (Pubitemid 351636126)
39. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001). (Pubitemid 32777772)
40. Tang K, Wong LP, Lee EJ, Chong SS, Lee CG. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum. Mol. Genet. 13(8), 783-797 (2004). (Pubitemid 38515208)
41. Hung CC, Chen CC, Lin CJ, Liou HH. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet. Genomics 18(5), 390-402 (2008).
42. Sissung TM, Baum CE, Deeken J et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin. Cancer Res. 14(14), 4543-4549 (2008).
43. Van Erp NP, Eechoute K, Van Der Veldt AA et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol. 27(26), 4406-4412 (2009).
44. Lemos C, Kathmann I, Giovannetti E, Calhau C, Jansen G, Peters GJ. Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2- mediated resistance to gefitinib and erlotinib. Br. J. Cancer 100(7), 1120-1127 (2009).
45. Thomas F, Rochaix P, White-Koning M et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur. J. Cancer 45(13), 2316-2323 (2009).
46. Villalona-Calero MA, Stinchcombe TE, Phelps MA et al. Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC. J. Clin. Oncol. 28(15 Suppl.), 7569 (2010).
47. Yeo WL, Riely GJ, Yeap BY et al. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J. Thorac. Oncol. 5(7), 1048-1053 (2010).
48. Costa DB, Kobayashi S, Yeo WL, Hamada A. Serum concentrations of erlotinib at a dose of 25mg daily. J. Thorac. Oncol. 5(8), 1311-1312 (2010).